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Introduction: The Scottish Medicines Consortium (SMC) provides 
advice about clinical- and cost-effectiveness of newly licensed medi-
cines to the National Health Service (NHS) in Scotland. Since 2005, 
SMC has also provided early intelligence on medicines in develop-
mentthrough “Forward Look” (FL) reports. An investigation was 
undertaken to examine the completeness of FL and its usefulness to 
NHS Boards.
Patients (or Materials) and Methods: (1) Significant medicines 
(with the potential for net budget impact exceeding UK£500,000 
per annum at year 5 and/or significant service implications or orphan 
status) in FL reports (April 2006-October 2008) were compared 
with SMC advice. The actual launch date was compared with the 
FL predicted date to determine if the medicine was launched within 
expected time frames. (2) SMC advice (April 2006 - March 2010) 
for all medicines was compared with FL reports. For medicines that 
were not included in FL reports but accepted by SMC, those predicted 
by the manufacturer to have a budget impact ≥ UK£500,000 were 
identified. (3) Interviews were held with NHS Directors of Finance 
and Directors of Pharmacy to explore how FL reports were used at 
NHS Board level.
Results: (1) Of 116 significant FL medicines, 81 (70%) medicines 
were reviewed by SMC; only 4 of the medicines not reviewed by SMC 
had been launched in the United Kingdom. A total of 52 (45%) of 
the 116 medicines were launched within time frames predicted by FL. 
Of the remaining 64 medicines, 31 were launched out with expected 
time frames; 31 were not launched in the UK; and, for 2 medicines, 
data were unavailable. (2) Of 215 medicines that were reviewed by 
SMC (April 2006 to March 2010), 123 (57%) medicines had been 
included in FL reports. Of the 92 (43%) medicines that were not 
included in FL reports, 53 were accepted for use or restricted use by 
SMC, including 7 medicines that were predicted by the pharmaceuti-
cal company to have a net budget impact ≥ £500,000 at year 5. (3) 
The qualitative study demonstrated that although NHS Boards did 
not view FL as completely accurate, it was a useful source of intel-
ligence on medicines in the pipeline and an important starting point 
for local clinical engagement.
Conclusion: Most significant medicines in FL reports were subse-
quently launched and reviewed by SMC. As expected, it was challeng-
ing to accurately predict the launch date of medicines in development, 
with many launched out with expected timef rames and some not 
launched at all. Despite the limitations, FL was considered a useful 
source of intelligence on medicines in the pipeline.
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Introduction: Self-medication increases the risk of overuse and 
innappropriate use of antibiotics with implications for increasing 
adverse events, treatment costs for individuals, and selection of resist-
ant bacteria in whole population.The aim of the present study was to 
analyze the amount and structure of antibiotics issued on prescription 
and bought without prescription and to investigate the influence of 
the price on the antibiotics consumption.
Patients (or Materials) and Methods: The investigation was carried 
out in the Novi Sad (323,708 inhabitants), Serbia, over a 3-month 
period, from January 1 to March 31, 2008. The data on the number 
of packages, size of packages, and retail price of antibiotics (ATC 
group J01) were obtained from all state-owned and private pharma-
cies in Novi Sad. The data are presented as number of DDD/1000 
inhabitants/d. Costs/DDD was also calculated. The DU90% meth-
odology was used.
Results: Seventy-six percent of antibiotics were issued by prescrip-
tion, while 23.94% were bought without prescription in Novi Sad. 
Penicillins, cephalosporins, and macrolides were the most prescribed 
antibiotic classes. By contrast, penicillins, tetracyclines, and cepha-
losporins were the most frequently bought antibiotics. The average 
price per DDD within the DU90% segment was 0.90 Euro/DDD 
for antibiotics issued by prescription, while for antibiotics bought 
without prescription, it was only 0.65 Euro/DDD, indicating that 
less expensive drugs were bought without prescription. The cheap-
est drug/DDD was doxycyclin (0.21 Euro/DDD) and it occupied the 
first position among antibiotics bought without prescription, while 
it was on the third place among antibiotics issued by prescription. 
The most expensive drugs/DDD were azithromycin (1.52 Euro/DDD) 
and ciprofloxacine (1.52 Euro/DDD). They occupied the high fourth 
and the eighth place among antibiotics issued by prescription. Among 
antibiotics bought without prescription, these expensive drugs occu-
pied the seventh and the eighth places.
Conclusion: The results of our study clearly show that a significant 
amount of antibiotics were dispensed in the private pharmacies with-
out prescription in Novi Sad, Serbia. The financial aspects strongly 
influence the antibiotics consumption without prescription. The influ-
ence of administrative measures, introduced recently on the usage of 
antibiotics, will be follow. This work was supported by the Ministry 
of Science and Technological Development, Republic of Serbia, pro-
ject No. 41012.
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Introduction: In resource-poor countries, access to essential medicines, 
and suboptimal prescribing and use of medicines, are major public health 
